Dr. Ansell on Incorporating Immunotherapies Beyond CAR T-Cell Therapy in NHL


Stephen M. Ansell, MD, PhD, discusses incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma (NHL).

Although CAR T-cell therapy is expensive and time consuming, the treatment is associated with high rates of durable responses, Ansell explains. As such, CAR T-cell therapy can elicit cures in a fraction of patients with NHL, Ansell adds. 

However, data with immunotherapies, such as tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid), are also demonstrating high rates of long-term, durable remissions, Ansell explains. As such, the overall utility of novel immunotherapies remains an unanswered question in NHL, Ansell says. However, they might offer a more accessible and cheaper alternative to CAR T-cell therapy without compromising efficacy, Ansell concludes.  

Related Videos
Peter Schmid, MD, PhD
Seema A. Khan, MD
Roisin E. O'Cearbhaill, MD
Stephen J. Freedland, MD
Tapan M. Kadia, MD,
Sara M. Tolaney, MD, MPH
Javier Cortés, MD, PhD,
Stephanie L. Graff, MD
Senthil Damodaran, MD, PhD
Eytan M. Stein, MD